MARKET

LUCD

LUCD

Lucid Diagnostics Inc.
NASDAQ
1.130
+0.020
+1.80%
After Hours: 1.120 -0.01 -0.89% 19:04 12/18 EST
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.140
LOW
1.100
VOLUME
791.31K
TURNOVER
--
52 WEEK HIGH
1.800
52 WEEK LOW
0.7501
MARKET CAP
155.58M
P/E (TTM)
-1.2600
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LUCD last week (1208-1212)?
Weekly Report · 3d ago
Lucid Diagnostics price target raised to $8.25 from $8 at Ascendiant
TipRanks · 12/10 15:15
Lucid Diagnostics Price Target Raised to $8.25/Share From $8.00 by Ascendiant Capital
Dow Jones · 12/10 10:39
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 12/10 10:39
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8.25
Benzinga · 12/10 10:29
Lucid Diagnostics’ esophageal precancer detection tools show efficacy in study
TipRanks · 12/09 13:16
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Barchart · 12/09 07:01
Lucid Diagnostics files for $175 mln mixed securities shelf offering
Seeking Alpha · 12/08 10:21
More
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Webull offers Lucid Diagnostics Inc stock information, including NASDAQ: LUCD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUCD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUCD stock methods without spending real money on the virtual paper trading platform.